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= 654) had statistically signiﬁcant lower PCS (−3.38, p < 0.001), MCS (−1.43, p < 
0.05), EQ-5D index (−0.024, p < 0.05), and VAS scores (−4.93, p < 0.001). Patients 
with diabetes also had signiﬁcantly lower HRQoL outcomes than those without 
diabetes (N = 43,326) (p < 0.001). CONCLUSIONS: In summary, macrovascular 
comorbidities signiﬁcantly decrease HRQoL in patients with diabetes.
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OBJECTIVES: This study was to compare health-related quality of life of patients 
with hypertension to people without hypertension. METHODS: Using the 2007 
NHANES of Korea, EuroQol (EQ-5D) was used to estimate a relation between quality 
of life and hypertension. In the analysis, adults (age ≥19 years old) at the time of the 
survey were included. EQ-5D as well as each 5 category such as mobility, self-care, 
usual activity, pain/discomfort and anxiety/depression were considered for the analy-
sis. For the estimation in EQ-5D, a generalized linear model with a logit link and the 
binomial family was used because EQ-5D was a proportion variable and had high 
negative skewness. In each speciﬁc category, there were 3 categories indicating good 
(1) to worse (3). Thus, ordered logit regressions were used for the analyses. In all 
analyses, age, gender, types of insurance, income, years of education and comorbid 
conditions were included. Survey weights were incorporated in the analyses to consider 
the survey design. RESULTS: A total of 2767 subjects was available. Among those, 
518 (18.7%) subjects had a hypertension based on self-report on whether they had 
hypertension or not. Mean (SD) in quality-of-life of patients with hypertension was 
0.84 (0.19), while mean (SD) of patients without hypertension was 0.93 (0.12). 
Among patients with hypertension, 51.7% were elderly (age >= 65 years) and 59.5% 
were female. Among patients without hypertension, 16.6% were elderly and 57.1% 
were female. Patients with hypertension as compare to people without hypertension 
were lower in quality of life by −0.20 (p-value: 0.038) after controlling other factors. 
Patients with hypertension were worsen in mobility and usual activity, but self-care, 
pain/discomfort and anxiety/depression had no difference from people without hyper-
tension. CONCLUSIONS: Patients with hypertension as compared to people without 
hypertension were lower in quality of life mostly due to difﬁculties in mobility and 
usual activity.
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OBJECTIVES: To characterize ACS-PCI patients including the index hospitalization 
charges and length-of-stay (LOS) in a US health beneﬁt plan. METHODS: The data 
source was Invision from i3, a division of UnitedHealth. ACS diagnoses were from 
ICD-9 codes 410.xx or 411.1. PCI procedure codes were 00.66, 36.0X, 92973, 92975, 
92978 −92982, 92984, 92995/6, and G0290/1. The deﬁnition of ACS-PCI was PCI 
within 30 days of an ACS diagnosis. The diagnosis related group (DRG) codes (555, 
556, 557, 558) and corresponding descriptions are from Version 23 and 24. Charges 
are in 2006 dollars. Continuous enrollment was required during the year 2006 and a 
minimum of 1 year before the index PCI. Patients with a history of transient ischemic 
attack or stroke were excluded. A clopidogrel claim was required within 60 days after 
hospitalization. RESULTS: Of the 6687 patients who had ACS-PCI and met the other 
inclusion criteria, 5174 (77.4%) were male, 5587 (83.6%) were under 65 years of 
age, and 1777 (26.6%) had a diabetes diagnosis. Drug-eluting stents (DES, n = 5541, 
82.9%) were frequently used. The 3249 patients with DRG557, DES with a major 
cardiovascular diagnosis (CVDx), had a mean length of stay (LOS) of 2.9 days and 
mean charges of $54,271. The 2292 patients with DRG558, DES without major 
CVDx, had a mean LOS of 1.7 days and mean charges of $44,230. The corresponding 
cohorts receiving bare metal stents (BMS) with (DRG555, n = 602) and without 
(DRG556, n = 187) major CVDx had mean LOS of 2.9 and 1.8 days with mean 
hospital charges of $46,106 and $34,109 respectively. CONCLUSIONS: For ACS 
patients who underwent PCI, the mean charge was approximately $10,000 higher and 
the mean LOS was 1 day longer for the cohort with major CVDx, as per the DRG 
deﬁnition, compared to the cohort without major CVDx.
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OBJECTIVES: Describe the management of ischemic stroke patients in acute phase 
and its impact on long-term stroke evolution in the USA. METHODS: Medline was 
searched from 1999 to date and ISPOR Digest was screened to identify stroke cohorts 
and registries containing data for the last ten years in the USA. A ranking process was 
implemented to identify and select the relevant references. RESULTS: A total of 461 
references were retrieved. The selection process led to the identiﬁcation of 78 publica-
tions (42 cohorts, 9 registries and 5 database studies) of which 41 focused on ischemic 
stroke only. Sixty-nine percent of the studies were hospital-based and 31% popula-
tion-based. The studies aimed to characterise determinants that impact acute phase 
management and outcomes, in particular demographic and clinical factors. Hospital 
settings and associated care facilities were studied in order to improve disease manage-
ment by identifying speciﬁc barriers to the administration of the only available throm-
bolytic treatment (recombinant tissue-type plasminogen activator, rt PA) in acute 
phase. Of these studies, many were not applicable to all ischemic stroke patients. 
Studies documenting the use of rt-PA showed that: less than 25% of patients arrived 
within 3 hours (i.e. time eligibility criteria for therapy) and 38.3% to 48.2% of them 
were excluded because of medical contraindications. Consequently, 10.9% to 14% of 
ischemic patients should have been given rt PA, but in natural settings, only 3.2% 
actually received it. In addition, long-term evolution of ischemic patients (mortality, 
stroke recurrence and cardiac events) was documented in several studies, but the evolu-
tion of disability after more than 3-months was not assessed. CONCLUSIONS: As 
shown above, general information about management of ischemic stroke in acute 
phase is lacking. New cohort or registry studies aiming to better describe patterns of 
ischemic stroke care that inﬂuence short and long-term clinical and associated eco-
nomic outcomes need to be developed.
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OBJECTIVES: The impact of Medicare’s Part D coverage gap (donut hole) on drug 
utilization was examined among patients with hypertension and/or hyperlipidemia, 
comparing treatment for asymptomatic (hypercholesterolemia and hypertension) and 
symptomatic (GI, depression, and pain) conditions. METHODS: The study sample 
consisted of patients from the 5% Medicare (A, B, and D) ﬁles with a diagnosis of 
hypertension and/or hyperlipidemia in 2005 and full-year (2006) fee-for-service, Medi-
care Part D and low-income subsidy (LIS) or non-LIS eligibility. Study outcomes 
included any drug use, adherence (percent days covered (PDC) ≥0.8), and discontinu-
ation (≥30-day continuous gap). The study employed a quasi-experimental design 
using a pre- (prior to donut hole) and post- (during donut hole) periods comparing 
three patient groups (non-LIS: without coverage, generic only coverage, and brand /
generic coverage during the gap) with a contemporaneous control group (LIS: no 
coverage gap). A difference-in-difference approach was used with multiple regressions 
controlling for demographic characteristics, Medicare entitlement status, area-level 
information, and clinical risk. RESULTS: The donut hole was associated with statisti-
cally signiﬁcant decreases in any drug use and PDC adherence, along with an increase 
in the likelihood of a discontinuation for both lipid lowering and antihypertensive 
drugs. The magnitude of impact was largest among patients without donut-hole drug 
coverage: 1.1% to 4.1% drop in probability of drug use; 4.4% to 12.1% decrease in 
adherence; and 4.5% to 12.5% increase in discontinuations (p < 0.01 for all). Impact 
was smallest among patients with both generic/brand drug coverage relative to the 
LIS controls. The donut hole had no impact on probability of using symptomatic drugs 
(anti-ulcer agents, antidepressants, and pain-killers). CONCLUSIONS: The donut 
hole was associated with statistically signiﬁcant but modest drops in the use of drugs 
for asymptomatic conditions, but had no impact on drugs for symptomatic conditions. 
Patients with no coverage during the donut hole experienced the largest impacts.
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OBJECTIVES: To assess the effect of Medicare Part D enrollment on changes in 
antihypertensive drug utilization for a nationally-representative sample of Medicare 
beneﬁciaries without prior prescription coverage. Part D enrollees have characteristics 
associated with above average drug use. To date, no nationally-representative studies 
have evaluated the impact of Part D on drug utilization controlling for these selection 
effects. Panel data methods address these biases in studying treatment for a chronic 
condition for which drug therapy can promote long term beneﬁts. METHODS: Lon-
gitudinal Medicare Current Beneﬁciary Survey (MCBS) data from the year before and 
after implementation of Part D. Unit of observation is the person-trimester, deﬁned 
as the interval between subsequent MCBS survey dates. Primary sample of beneﬁcia-
ries reporting a diagnosis of hypertension without drug coverage in 2005 and com-
pleted all 6 survey rounds in 2005 and 2006 (N = 3039 person trimesters). Secondary 
control sample of beneﬁciaries continuously enrolled in employer-sponsored insurance 
(ESI) as a sensitivity analysis (N = 5,608 person trimesters). Fixed effects and differ-
ence-in-difference (DID) multivariate methods compare changes in drug ﬁlls over six 
4-month periods for beneﬁciaries who enrolled in Part D and those who did not. 
RESULTS: A total of 67% of the primary sample enrolled in Part D. Descriptive trend 
analysis shows a monotonic increase in mean antihypertensive ﬁlls by trimester 
ranging from 4.0 to 7.1 for Part D enrollees, compared to a range from 2.7 to 4.4 for 
non-enrollees. In adjusted DID comparisons, Part D enrollees experienced 1.79 addi-
tional antihypertensive ﬁlls per trimester relative to non-enrollees (p < 0.05). Fixed 
effects methods suggest that Part D enrollees ﬁlled an additional 1.08 prescriptions 
per trimester (p < 0.05). Sensitivity analysis show comparable results. CONCLU-
SIONS: Enrollment in Part D increased drug utilization for a class of drugs known to 
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be effective in treating a highly prevalent, costly, and asymptomatic condition such as 
hypertension.
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OBJECTIVES: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin 
receptor blockers (ARBs) have substantially contributed to the escalating antihyper-
tensive drug cost in Taiwan. Increasing literature has proposed potential beneﬁts of 
combing ACEIs/ARBs in controlling blood pressure, but there is still a lack of evidence 
to support the rationale of ACEIs/ARBs combination in treating hypertension. This 
study aims to explore the current utilization and prescribing patterns of ACEIs/ARBs 
combination in Taiwan. METHODS: A cross-sectional study was conducted from 
2006 to 2008, using a regional reimbursement claim database from the KaoPing Divi-
sion of National Health Insurance. Individual data of hypertensive outpatients treated 
with ACEIs or ARBs for more than 28 days per year in Southern Taiwan were 
extracted. Demographic and prescribing data were collected, and then descriptive 
analyses were used to evaluate patients’ characteristics and prescribing patterns of 
ACEIs, ARBs and their combination. Wald chi-square tests and Student’s t-test were 
conducted to examine the prescribing associated variables and differences between 
health care facilities. RESULTS: During the 3-year study period, 4,482,826 prescrip-
tions were assessed, including 44.69% (n = 2,003,278) ACEIs and 55.31% (n = 
2,479,548) ARBs prescriptions. Of all, 1.22% (n = 54,526) prescriptions have either 
doubled or combined more than one ACEI. Likewise, 2.29% (n = 102,486) have 
doubled or combined ARBs. Furthermore, 0.61% (n = 27,381) prescriptions combined 
both ACEIs and ARBs. The majority of these combinations were prescribed in medical 
centers in continuous prescriptions for long-term reﬁlls, and the amount of combined 
prescriptions increased annually. The major co-morbidity of ACEIs/ARBs combina-
tions is diabetes mellitus (n = 9871, 36.05%), and chronic renal disease (n = 5055, 
18.46%) and congestive heart failure (n = 886, 3.24%). CONCLUSIONS: We found 
a small proportion of ACEIs/ARBs combination, yet the combined prescriptions are 
increasing and used chronically in patients with speciﬁc co-morbidities. Further studies 
are needed to explore the effectiveness and rationality of this combination.
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OBJECTIVES: Upon the coverage limitations proposed by Taiwan National Health 
Insurance (NHI), the dual therapy with clopidogrel and aspirin would be reimbursed 
up to 9 months for speciﬁc indications since 2004. Although evidence showed its risks 
outweighed the beneﬁts comparing to use aspirin alone, it is a lack of study examining 
population use of dual therapy. A secondary data analysis was performed to examine 
the use patterns of dual antiplatelet therapy (DAT), speciﬁcally among older adults in 
Taiwan. METHODS: A population-based longitudinal assessment was conducted 
using the 2003–2007 NHI databases. Those beneﬁciaries in 60 years old of age and 
greater during the study period were evaluated. All relevant data, including visits 
toward physician clinics, outpatient departments, use of medications, and pertinent 
coverage cost in the datasets of ambulatory care were retrieved and analyzed. Descrip-
tive analysis was performed to describe and compare the utilization of DAT for less 
or greater than 3 months (shorter vs. longer treatment). RESULTS: Of half million 
beneﬁciaries being evaluated, 1099 patients were prescribed DAT. Of which, 71% 
were older adults (age = 71 ± 7.8 years old). There was a sharply increasing utilization 
of DAT in 2007 for a total of 785 older patients. 85% were prescribed with approval 
indications (i.e., ischemic heart diseases) for aspirin or clopidogrel alone. 29.8% pos-
sessed with at least one atherothrombotic risk factors (DM, dyslipidemia), which 
might attribute to DAT. The duration of DAT was up to 13 months. The total drug 
expenses were 66% and 85% among shorter and longer treatment patients, respec-
tively. The cost of DAT accounted for up to 51% of total drug expense. CONCLU-
SIONS: There were sharply increasing utilization of DAT among Taiwanese older 
adults since 2007. Further studies are needed to explore the contributing factors of 
DAT and its effectiveness and safety outcomes.
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OBJECTIVES: The prevalence of hypertension is increasing in epidemic proportions 
in the Indian subcontinent. Despite the well known beneﬁts of aggressive blood pres-
sure control in hypertensive patients, data from the subcontinent indicate that the 
control of hypertension remains remarkably poor. Our previous study demonstrated 
that calcium channel blockers (CCBs) were the most prescribed agents for uncompli-
cated hypertension in three South Indian Hospitals. The objective of this study was 
to assess the physician’s perspectives with regard to antihypertensive pharmacotherapy 
and to determine whether they are in accordance to national and/or international 
hypertension guidelines. METHODS: A questionnaire was developed containing ques-
tions on familiarity with guidelines, diagnosis of clinical hypertension, and evaluation 
of patients with hypertension with or without co-morbidities, treatment of hyperten-
sion including choice of drugs, and drug regimens or speciﬁc drug combinations. The 
questionnaire was administered to interns and physicians of Medicine Department of 
three teaching-hospitals in South India. RESULTS: Among a total of 57 physicians 
who received the survey 58.1% expressed familiarity with the JNC-VII guidelines 
whereas 12.8% were familiar with the Indian Hypertension Guidelines-II. Although 
majority of the physicians were aware of the guidelines about 37% of them indicated 
that they would prefer CCBs as the ﬁrst drug for treating uncomplicated hypertension. 
When asked about monotherapy versus combination therapy a majority (91.2%) of 
the physicians chose a two-drug combination over monotherapy. CCB with ACE-
inhibitors was the most favored choice followed by combinations of CCBs with 
beta-blockers and diuretics. CONCLUSIONS: The physician’s preference of CCBs and 
combination therapy over other antihypertensives and monotherapy may be attributed 
to the better treatment outcomes they experienced and is consistent with emerging 
trends observed in recent studies such the ACCOMPLISH and ASCOT trials that 
underscore the beneﬁts of using combination therapy with CCBs as initial therapy for 
hypertension.
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OBJECTIVES: This study evaluates changes in utilization patterns of class I (ﬂecainide 
and propafenone) and class III (amiodarone) antiarrhythmics in France, Italy, Spain, 
Germany, and the UK from 2005 to 2009. These drugs are used for treatment of 
supraventricular and ventricular arrhythmias of which atrial ﬁbrillation is the most 
common among the adult population. METHODS: Utilization trends were examined 
using IMS Market Trend Analysis, a database of global sales from all corporations 
with pharmaceutical products sold into a pharmacy or hospital as well as prescription 
information from ofﬁce-based physicians. Utilization of antiarrhythmic drugs was 
assessed using patient days of therapy (PDoT). Descriptive analyses were conducted 
for speciﬁc drug classes as well as individual agents, including ﬂecainide, propafenone, 
and amiodarone. RESULTS: Overall, PDoT was highest for amiodarone, the main 
representative class III agent, with an average of 229 million PDoT over the ﬁve year 
period across all markets. During this time, PDoT for amiodarone increased by 9.5% 
in Italy (50.9 to 55.7 million), 13.8% in Germany (32.9 to 37.5 million), and 0.5% 
in France (85.8 to 86.3 million) and decreased by 20.6% in the UK (32.8 to 26.0 
million) and 2.5% in Spain (27.2 to 26.5 million). This resulted in greater class III 
drug use in all markets except Italy, where class I agents were preferred over class III 
agents consistently from 2005 to 2009. Among all antiarrhythmics, ﬂecainide showed 
a consistent overall increase in PDoT over the study period, with a 22.4% increase 
from 110 to 135 million PDoT and a resulting increase in market share from 24% to 
29.4% from 2005 to 2009. CONCLUSIONS: Amiodarone was the dominant antiar-
rhythmic in all markets. However, increases in ﬂecainide use in 4 out of 5 European 
markets suggest a possible change in rhythm control strategy for the treatment and/
or management of arrhythmias.
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OBJECTIVES: In January 2009, an authorization form was implemented which 
required Dutch clinicians to justify the prescription of branded statins, leading to 
signiﬁcant switching of patients from atorvastatin to generic simvastatin. However, 
current prescription data indicates that much of this switching is occurring at less than 
equipotent doses. We sought to assess the potential consequences in terms of cardio-
vascular disease. METHODS: Data from a pharmacy database covering the majority 
of drug dispenses in the The Netherlands informed dose-speciﬁc patterns of switching 
from atorvastatin to generic simvastatin. Dose-speciﬁc, LDL-C-modifying potencies of 
the two statins were derived from a recently-published meta-analysis. The relationship 
between reduction in LDL-C achieved by statin therapy and relative reduction in risk 
of coronary and stroke risk was derived from a recently-published meta-regression. 
This showed that for every 0.65 mmol/L (25 mg/dL) reduction in LDL-C, the relative 
risk (RR) (95% conﬁdence interval [CI]) for a coronary and stroke event were 0.84 
(95%CI 0.82–0.86) and 0.90 (95%CI 0.86–0.94), respectively. RESULTS: Out of the 
39,031 Dutch patients who were switched from atorvastatin to generic simvastatin in 
the ﬁrst quarter of 2009, 33.7%, 47.2% and 19.1% were switched to less potent, 
equipotent and more potent doses of simvastatin, respectively. The net (weighted-
average) effect would have been a 5.6% increase in LDL-C. Assuming a baseline 
LDL-C of 2.5 mmol/L (98 mg/dL), the predicted relative increases (95%CI) in the 
risks of coronary and stroke events were 3.4% (3.0–3.9%) and 2.1% (1.3–3.0%), 
respectively. The equivalent ﬁgures for a baseline LDL-C of 3.0 mmol/L (117 mg/dL) 
were 4.1% (3.6–4.6%) and 2.6% (1.5–3.6%), and for a baseline LDL-C of 3.5 mmol/L 
(137 mg/dL), they were 4.8% (4.2–5.4%) and 3.0% (1.8–4.2%). CONCLUSIONS: 
